Clinical Trials Directory

Trials / Completed

CompletedNCT05164003

CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase1)

A Randomized, Double-blind, Active Drug Controlled, Multi-Center, Phase I/III Clinical Trial to Evaluate the Efficacy and Safety of CORETOX® in Treatment of Post Stroke Upper Limb Spasticity

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Medy-Tox · Industry
Sex
All
Age
19 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the safety and pharmacodynamic of CORETOX® in the treatment of post-stroke upper limb spasticity

Conditions

Interventions

TypeNameDescription
DRUGCORETOX®Up to a total of 360U of the IP was allowed to be injected at three flexors; wrist, elbow and finger.
DRUGBOTOX®Up to a total of 360U of the comparator was allowed to be injected at three flexors; wrist, elbow and finger.

Timeline

Start date
2017-07-17
Primary completion
2017-09-29
Completion
2017-09-29
First posted
2021-12-20
Last updated
2022-01-11

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT05164003. Inclusion in this directory is not an endorsement.

CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase1) (NCT05164003) · Clinical Trials Directory